论文部分内容阅读
米那普仑(milnacipran)是一种5-羟色胺(5-HT)和去甲肾上腺素(NE)双回收抑制剂,可用于抑郁障碍、脑外伤后抑郁、卒中后抑郁[1]、Alzheimer病伴发抑郁[2]、广泛性焦虑障碍[3]、惊恐障碍[4]、纤维肌痛症[5]、预防偏头痛发作[6]、神经病理性疼痛[7]、幻肢痛[8]等疾病的治疗。随着其在临床上的广泛应用,对其不良反应
Milnacipran is a dual-recoverable 5-hydroxytryptamine (5-HT) and norepinephrine (NE) inhibitor that can be used for depressive disorders, depression after traumatic brain injury, and post-stroke depression [1], Alzheimer’s disease Generalized anxiety disorder 3, panic disorder 4, fibromyalgia 5, prevention of migraine attacks 6, neuropathic pain 7, phantom limb pain 8, Treatment of diseases. With its wide range of clinical applications, its adverse reactions